Be Gone Smoking

Dieffenbachia Seguine - Daphne Odora Bark - Strychnos Nux-vomica Seed - Plantago Major - Delphinium Staphisagria Seed - Tobacco Leaf


Washington Homeopathic Products
Human Otc Drug
NDC 68428-731
Be Gone Smoking also known as Dieffenbachia Seguine - Daphne Odora Bark - Strychnos Nux-vomica Seed - Plantago Major - Delphinium Staphisagria Seed - Tobacco Leaf is a human otc drug labeled by 'Washington Homeopathic Products'. National Drug Code (NDC) number for Be Gone Smoking is 68428-731. This drug is available in dosage form of Pellet. The names of the active, medicinal ingredients in Be Gone Smoking drug includes Daphne Odora Bark - 6 [hp_C]/28g Delphinium Staphisagria Seed - 6 [hp_C]/28g Dieffenbachia Seguine - 6 [hp_C]/28g Plantago Major - 6 [hp_C]/28g Strychnos Nux-vomica Seed - 6 [hp_C]/28g Tobacco Leaf - 6 [hp_C]/28g . The currest status of Be Gone Smoking drug is Active.

Drug Information:

Drug NDC: 68428-731
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Be Gone Smoking
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Otc Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Dieffenbachia Seguine - Daphne Odora Bark - Strychnos Nux-vomica Seed - Plantago Major - Delphinium Staphisagria Seed - Tobacco Leaf
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Washington Homeopathic Products
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Pellet
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:DAPHNE ODORA BARK - 6 [hp_C]/28g
DELPHINIUM STAPHISAGRIA SEED - 6 [hp_C]/28g
DIEFFENBACHIA SEGUINE - 6 [hp_C]/28g
PLANTAGO MAJOR - 6 [hp_C]/28g
STRYCHNOS NUX-VOMICA SEED - 6 [hp_C]/28g
TOBACCO LEAF - 6 [hp_C]/28g
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:ORAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: UNAPPROVED HOMEOPATHIC
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 01 Mar, 2013
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 16 Jan, 2025
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:Washington Homeopathic Products
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
UPC:0740640130933
UPC stands for Universal Product Code.
NUI:N0000185375
N0000175629
N0000184306
N0000185001
M0000728
M0016962
M0516536
Unique identifier applied to a drug concept within the National Drug File Reference Terminology (NDF-RT).
UNII:JSJ34YQJ5D
00543AP1JV
01800C6E6B
W2469WNO6U
269XH13919
6YR2608RSU
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.
Pharmacologic Class EPC:Non-Standardized Plant Allergenic Extract [EPC]
Established pharmacologic class associated with an approved indication of an active moiety (generic drug) that the FDA has determined to be scientifically valid and clinically meaningful. Takes the form of the pharmacologic class, followed by `[EPC]` (such as `Thiazide Diuretic [EPC]` or `Tumor Necrosis Factor Blocker [EPC]`.
Pharmacologic Class PE:Increased Histamine Release [PE]
Cell-mediated Immunity [PE]
Increased IgG Production [PE]
Physiologic effect or pharmacodynamic effect—tissue, organ, or organ system level functional activity—of the drug’s established pharmacologic class. Takes the form of the effect, followed by `[PE]` (such as `Increased Diuresis [PE]` or `Decreased Cytokine Activity [PE]`.
Pharmacologic Class CS:Allergens [CS]
Plant Proteins [CS]
Seed Storage Proteins [CS]
Chemical structure classification of the drug product’s pharmacologic class. Takes the form of the classification, followed by `[Chemical/Ingredient]` (such as `Thiazides [Chemical/Ingredient]` or `Antibodies, Monoclonal [Chemical/Ingredient].
Pharmacologic Class:Allergens [CS]
Cell-mediated Immunity [PE]
Increased Histamine Release [PE]
Increased IgG Production [PE]
Non-Standardized Plant Allergenic Extract [EPC]
Plant Proteins [CS]
Seed Storage Proteins [CS]
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
68428-731-291 BOTTLE, PLASTIC in 1 BOX (68428-731-29) / 28 g in 1 BOTTLE, PLASTIC01 Mar, 2013N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Purpose:

Uses aids the body in regaining healthy balance during the smoking cessation process.

Product Elements:

Be gone smoking dieffenbachia seguine - daphne odora bark - strychnos nux-vomica seed - plantago major - delphinium staphisagria seed - tobacco leaf sucrose lactose dieffenbachia seguine dieffenbachia seguine daphne odora bark daphne odora bark strychnos nux-vomica seed strychnos nux-vomica seed plantago major plantago major delphinium staphisagria seed delphinium staphisagria seed tobacco leaf tobacco leaf white

Indications and Usage:

Indications indications: caladium motion sickness daphne bad breath nux vom vomiting plantago earache staphysag anger tabacum sea sickness

Warnings:

Stop use and ask doctor if symptoms persist or recur, discontinue use. if pregnant or nursing a baby, consult a licensed practitioner before using this product. *claims based on traditional homeopathic practice, not accepted medical evidence. not fda evaluated.

Dosage and Administration:

Directions adults 2 pellets every 3 hours for 2 days. then 2 pellets morning and night for 2 weeks. children: 1 pellet. repeat as necessary.

Package Label Principal Display Panel:

Principal display panel be g one tm smoking label be g one tm smoking box box label


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.